Don’t let the high cost of brand two-drug single-tablet HIV regimens disrupt your treatment. We help eligible patients access Dovato (dolutegravir/lamivudine) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Dovato Prescription Assistance Program is a manufacturer-sponsored initiative that provides Dovato at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HIV treatment patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, HIV provider coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$3,700.00 | Save ~$3,630/mo |
| CVS Pharmacy | ~$3,800.00 | Save ~$3,730/mo |
| Walmart | ~$3,500.00 | Save ~$3,430/mo |
| Costco | ~$3,450.00 | Save ~$3,380/mo |
Kroger | ~$3,500.00 | Save ~$3,430/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Dovato at no medication cost if approved. Our $69.95/month service covers full advocacy.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Dovato:
Still $3,400–$3,800 per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Dovato assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Dovato (DTG/3TC) is a once-daily, single-tablet, two-drug HIV-1 regimen combining the integrase strand transfer inhibitor (INSTI) dolutegravir and the NRTI lamivudine. It is the first two-drug single-tablet regimen approved for first-line HIV therapy and demonstrates that effective HIV treatment can be achieved with fewer drug exposures.
How Dovato Works:
Traditional HIV therapy uses three antiretroviral agents. Dovato challenges that paradigm — combining a high-barrier-to-resistance INSTI (dolutegravir) with a single NRTI (lamivudine), achieving similar viral suppression with only two drugs.
Dolutegravir blocks integrase to prevent HIV DNA from integrating into host DNA — and has a particularly high genetic barrier to resistance. Lamivudine is an NRTI that incorporates into the growing viral DNA chain and terminates elongation. Together, in patients without resistance to either component, the two-drug combination suppresses HIV-1 effectively in most situations — sparing patients from long-term tenofovir or abacavir exposure.
Form and use:
Dovato is taken as one tablet by mouth once daily, with or without food. Avoid taking with calcium, iron, magnesium, or aluminum supplements within 2 hours before or 6 hours after (these reduce dolutegravir absorption).
Generic availability:
There is no generic Dovato in the U.S. as of 2026. Generic lamivudine is widely available, and dolutegravir is available separately as Tivicay. Other single-tablet regimens include Biktarvy (BIC/FTC/TAF, three-drug), Triumeq (DTG/ABC/3TC, three-drug), Genvoya (EVG/c
Warnings:
Dovato carries a BOXED WARNING for severe acute HBV exacerbation if discontinued in patients with HBV co-infection — Dovato is not recommended for HIV/HBV co-infected patients without adequate alternative HBV therapy, because lamivudine alone is insufficient for HBV. Other warnings include hepatotoxicity (especially with HBV/HCV co-infection), neural tube defects with first-trimester dolutegravir exposure (initial concern from preliminary data, now mostly reassured by larger studies), hypersensitivity reactions, depression/suicidality, and immune reconstitution syndrome.
Dovato costs approximately $3,400–$3,800 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Dovato at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Most HIV regimens use three antiretrovirals. Dovato demonstrates that highly effective viral suppression can be achieved with just two drugs — dolutegravir (a high-barrier-to-resistance INSTI) and lamivudine (an NRTI). The advantage is fewer drug exposures over many years of therapy, potentially reducing long-term toxicity from tenofovir or abacavir. Dovato is appropriate for patients without resistance to either drug and with HIV-1 RNA ≤500,000 copies/mL at start.
Dovato is not appropriate for patients with hepatitis B co-infection (lamivudine alone isn’t sufficient HBV coverage and can lead to HBV resistance — and stopping Dovato can cause HBV flares), patients with HIV-1 RNA >500,000 copies/mL at start, or patients with known resistance to dolutegravir or lamivudine. HIV/HBV co-infected patients typically need a tenofovir-containing regimen (Biktarvy or others).
Polyvalent cations (calcium, iron, magnesium, aluminum, zinc) significantly reduce dolutegravir absorption. Take Dovato either 2 hours before or 6 hours after any cation-containing supplement or antacid. Plain vitamin pills usually contain small amounts of these — discuss with your prescriber and pharmacist.
Both are once-daily, single-tablet, INSTI-based regimens with high resistance barriers. Dovato is a two-drug regimen (DTG/3TC). Biktarvy is a three-drug regimen (BIC/FTC/TAF) with broader HBV coverage. Dovato avoids tenofovir; Biktarvy includes tenofovir alafenamide. The choice depends on hepatitis B status, baseline viral load, prior resistance, and patient preferences.
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. State ADAP programs may also coordinate with Medicare for HIV-treatment patients.
If denied, we explore alternatives — switching to another INSTI-based regimen with its own PAP (Biktarvy, Triumeq, Genvoya), state ADAP, the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee.Generic oral valacyclovir highly effective and very cheap.
If you are struggling with the high cost of Dovato, our team may be able to help you access assistance programs designed to make brand single-tablet HIV regimens affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.